Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Bronchial Asthma
Interventions: Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo; Drug
Lead sponsor: Cipla Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Medford, Oregon

Conditions: Asthma, Atopy
Interventions: fluticasone, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 6 more

Conditions: Asthma
Interventions: Ciclesonide (XRP1526); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Asthma
Interventions: BI 671800, Placebo, Montelukast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16,568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 506
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 85
States / cities: Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 17,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 303
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more

Conditions: Asthma
Interventions: Asthma in-school class, Asthma Day Camp, Health Promotion in-school class; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Years to 13 Years
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: COPD, Diabetes, Hypertension
Interventions: Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable); Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Conditions: Asthma
Interventions: Placebo, Fluticasone; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 6,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 190
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Placebo, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Kissimmee, Florida • Louisville, Kentucky • Bend, Oregon

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 25
States / cities: Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more

Conditions: Asthma
Interventions: AZD8630, Placebo, Inhaler; Drug · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 45
States / cities: Mesa, Arizona • Huntington Beach, California • La Mesa, California + 41 more

Conditions: Covid19
Interventions: Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 10,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 110
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Conditions: Healthy Adult Volunteers
Interventions: Drug: OP0201, Drug: Placebo; Combination Product
Lead sponsor: Novus Therapeutics, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 58
States / cities: Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more

Conditions: Asthma
Interventions: Placebo, Tiotropium low dose mcg, Tiotropium high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 10
States / cities: Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more

Search by objective public record fields.

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Asthma in Central Texas Project

Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

Repeated High-dose Inhaled Corticosteroids for Asthma

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

ACTIV-6: COVID-19 Study of Repurposed Medications

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Efficacy and Safety Study of QVA149 in COPD Patients

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma